Effect of pioglitazone, as antidiabetic agent, on atheroma regression in type 2 diabetic patients: a systematic review and meta-analysis

Antoine Fakhry AbdelMassih 1*, Ahmed Ashraf 2, Habiba-Allah Ismail 2, Bassant AbdelAzeim 2, Ihab Hany Barsoum 2, Shady Girgis 2, George Afdal 2, Nesrine AbdelAzeim 2, Peter Afdal 2, Esraa Menshawey 2, Rahma Menshawey 2, Kirollos Badr 2 and Mariem Arsanyous 2

Abstract

Background: Pioglitazone's role in the induction of atheroma regression in diabetics was suggested by several RCT. The aim of our study was to evaluate this role through a systematic review of all RCT conducted on this subject.

Methods: Literature was searched for relevant studies. We included all RCT that compared pioglitazone versus other antidiabetic agents. Mean differences of either AV or CIMT, HbA1C, HDL, and LDL between the two groups were used to assess the effect of pioglitazone versus alternative therapies.

Results: Six RCT were included with a total of 1180 patients. Pioglitazone was significantly superior to glimepiride and gliclazide in improving IMT. No significant difference was observed in overall AV, HbA1C, and LDL.

Conclusion: The latter findings confirm that anti-atheroma action of pioglitazone is not achieved through its antiglycemic or antidyslipidemia effects, but probably through a DNA-mediated effect, and may lead to its repurposing for reversal of organ fibrosis.

Keywords: Pioglitazone, Antiatherogenic effect, Regenerative medicine, Metabolic syndrome, Type 2 diabetes mellitus

1 Background

Regenerative medicine is a relatively new term in modern medicine that has flourished over the last four decades. It includes any drug or intervention that can induce regeneration of human cells, tissues, and organs with the intention of reestablishing normal functionality. The main focus of regenerative medicine was organ and stem cell transplantation [1]. However, new bodies of evidence suggest the increasing role of drugs as part of regenerative medicine. Regenerative pharmacology suggests that drugs might be used to induce complete regeneration of certain organs by exerting effects on nuclei and deoxyribonucleic acid (DNA) [2]. Recently, Afdal et al. suggested a potential role of peroxisome proliferator-activated receptor (PPAR) γ agonists in the induction of regression pulmonary vascular disease, which might be regarded as a breakthrough to eliminate, with time, the need for heart-lung transplantation [3, 4]. PPAR γ agonists, especially pioglitazone, act by epigenetic mechanisms to alter DNA expression and therefore play a crucial role in triggering organ reverse remodeling at multiple levels [5, 6]. This effect has encouraged many scientists over the years to study the effect of pioglitazone on atheroma regression. Atheroma is the key lesion in macrovascular disease seen in patients with metabolic
syndrome [7–12]. Along with its cardiac and cerebral sequelae, it is regarded as the number one cause of death worldwide. The estimates from the World Health Organization suggest that up to 31% of deaths worldwide are atheroma related [13]. The primary outcome parameter of this study was to use the totality of previous randomized clinical trials on the effect of pioglitazone on atheroma regression, by quantitatively evaluating its potential ability to do so through its effect on atheroma volume (AV), and carotid intima media thickness (CIMT), as well determine through which secondary outcome parameters pioglitazone was inducing such changes by determining any correlation between its use and glycated hemoglobin (HbA1c), low-density lipoproteins (LDL), and high-density lipoprotein (HDL) levels.

2 Materials and methods

This systematic review has been conducted in agreement with the guidelines of the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) statement [14].

2.1 Data search

An electronic search for relevant studies was performed using EMBASE, Medline, and the Cochrane Central Register (January1990 to January 2019) of Controlled Trials.

2.2 Study selection criteria

2.2.1 Inclusion criteria

Population: diabetic and non-diabetic patients with carotid/coronary atheroma

Intervention: pioglitazone ± standard therapy/control: placebo or no treatment ± standard therapy/outcomes: atheroma volume by intravascular ultrasound (IVUS) or by carotid intima media thickness/study design: randomized controlled trials (RCT) [15]

2.2.2 Exclusion criteria

Any study that failed to tackle the primary outcome parameters or was lacking the patients’ characteristics

2.3 Data extraction

All data from eligible studies were extracted by two independent investigators according to a standard protocol. Recorded data variables included trial name, year of publication, country of origin, eligibility criteria, baseline characteristics, duration of follow-up, and number of participants. Other variables considered were standardized mean difference of atheroma volume or carotid

| Table 1 | Summary statistics of the studied populations in the 6 selected studies |
|---------|------------------------------------------------------------------------|
| **Trial** | **Steven E. Nissen et al. [8]** | **Mazzone et al. [12]** | **Kanazawa et al. [11]** | **Nakayama, et al. [10]** | **Park et al. [9]** | **Ogasawara, et al. [7]** |
| Publication year | 2008 | 2006 | 2010 | 2010 | 2007 | 2009 |
| Country | North and South America | USA Chicago | Japan | Japan | Korea | Japan |
| Active/control | Pioglitazone vs glimepiride | Pioglitazone vs glimepiride | Pioglitazone vs metformin | Pioglitazone vs standard therapy (control) | Pioglitazone vs gliclazide (control) | Pioglitazone vs group with their previous anti diabetic regimen (control) |
| Sample size | 543 patients with type 2 diabetes and coronary disease | 462 adults with type 2 diabetes | 55 patients with type 2 diabetes mellitus | 26 patients with stable angina and type 2 diabetes | 40 patients with type 2 diabetes | 54 patients with type 2 diabetes and stable angina pectoris |
| Age in years (mean ± SD) | 60 ± 9.4 P/59.7 ± 9.1 C | 58.9 ± 7.8 P/59.8 ± 8.1 C | 67 ± 10 P/66 ± 10 M | 670 ± 7.5 P/630 ± 10.5 C | 63.1 ± 7.2 P/642 ± 7.1 C | 686.7 ± 7.9 P/668 ± 8.1 C |
| Baseline HbA1c, % (mean ± SD) | 7.4 ± 1 P/7.4 ± 1 C | 7.44 (1.01) P/ 7.36 (0.95) G | 7.19 ± 1 P/7.9 ± 1.3 M | 6 ± 1.3 P/5.4 ± 0.9 C | 9.0 ± 2.3 P/8.8 ± 2.2 C | 7.17 ± 0.72 P/6.80 ± 0.85 C |
| Baseline fasting glucose, mg/dL (mean ± SD) | 147.2 ± 41 P/148 ± 43.4 C | 149.2 (48.3) P/148.2 (44.7) C | Not supplied | 103 ± 12 P/99 ± 12 C | 9.85 ± 1.27 P/9.51 ± 0.96 C | 139.3 ± 35.3 P/129.2 ± 27.0 C |
| BMI (mean ± SD) | 32.1 ± 5.3 P/32 ± 5.2 C | 32.2 ± 5.1 P/32.0 ± 5.1 C | 220 ± 2.3 P/249 ± 3.7 | Not supplied | 24.3 ± 4.1 P/24.1 ± 3 C | 23.8 ± 3.0 P/24.1 ± 2.1 C |
| Median follow-up | 18 months | 72 weeks | 12 months | 6 months | 3 months | 6 months |
| Changes from baseline to year 1 or final visit | | | | | | |
| HbA1C post ttt (diabetics/non-diabetics) (mean ± SD) | 6.9 ± 0.9 P/7 ± 1 C | Not supplied | 7.1 ± 1.2 P/7.1 ± 1.1 C | 5.8 ± 0.8 P/5.3 ± 0.8 C | 7.1 ± 1.3 P/7.1 ± 1.2 C | 6.50 ± 1.05 P/6.81 ± 0.87 C |
| Fasting glucose post ttt (diabetics/non-diabetics) (mean ± SD) | 139.3 ± 29.1 P/147.9 ± 33.8 C | Not supplied | Not Supplied | 97 ± 14 P/102 ± 21 C | 7.95 ± 1.03 P/7.47 ± 0.74 C | 113.7 ± 28.9 P/137.8 ± 39.8 C |

C controls, P pioglitazone group, SD standard deviation, TTT Treatment
intima media thickness, glycated hemoglobin (HbA1C), low-density lipoproteins (LDL), and high-density lipoproteins (HDL) in recipients of pioglitazone vs. controls (recipients of other antidiabetic drugs). We assessed study quality using the Cochrane risk-of-bias algorithm.

2.4 Statistical analysis
Mean differences in atheroma volume by intravascular ultrasound or carotid intima media thickness (CIMT) were all included as primary outcome parameters for comparison between pioglitazone versus control. We calculated the standardized mean difference and their corresponding 95% CIs. For the statistical analysis, we used a random-effects model and explored for sources of inconsistency ($I^2$) and heterogeneity. We considered study-level estimates to be heterogeneous if the $\chi^2$ test was significant ($P < 0.05$). The Cochrane Collaborations Review Manager Software Package (RevMan 5.3) was used for this meta-analysis. Tests for heterogeneity, as well as $Z$ test and $P$ values, were determined for secondary outcome parameters including HbA1c, LDL, and HDL.

3 Results
3.1 Main findings
The literature review identified 10 studies that were deemed suitable for detailed assessment, four of which were excluded. Koshiyama et al.’s [16] study was excluded due to the lack of patient characteristics which might induce a major selection bias. Nozue et al.’s [17] series was excluded due to lack of comparison between a pioglitazone group and a control group; comparison was conducted between a diabetes mellitus (DM) group and a non-DM group. Finally, Dormandy et al. and Liu et al. [18, 19] were excluded due to different clinical endpoints or outcome parameters than those previously mentioned, namely CIMT and atheroma volume by IVUS.

Six studies were ultimately included with a totality of 1990 patients.

Patient characteristics have been summarized for each study in Table 1.

Pioglitazone use showed a statistically significant superior effect on CIMT compared to other antidiabetic therapies ($P < 0.001$) (Fig. 1). In contrast, pioglitazone did not achieve a superior effect in decreasing atheroma volume as assessed by IVUS (Fig. 2). Furthermore, examination of secondary outcome parameters revealed no superior effect of pioglitazone use in reduction of HbA1c and LDL levels ($P = 0.11$ and $P = 0.97$ respectively) (Figs. 3 and 4). HDL levels were significantly improved with the use of pioglitazone ($P < 0.00001$) (Fig. 5). This strongly suggests that the means through which pioglitazone affects carotid intima media thickness is by an HDL-mediated anti-inflammatory and antifibrotic function.

3.2 Bias assessment of the quality of included RCTs
Any potential bias has been discussed in Fig. 6, according to the revised Cochrane risk-of-bias tool for randomized trials [20]. The main limitation that can interfere with the credibility of these results is the lack of
uniformity of outcome parameters assessed in the differ-
ent studies. Three studies only assessed the CIMT [9, 11, 12], while the other three assessed the AV [7, 8, 10].
Kanazawa et al. did not assess all the secondary outcome
parameters [11]. Finally, yet importantly, Mazzzone et al.
did not assess LDL [12]. Another important source of
bias is the lack of variability of races in the included tri-
als. Most of the trials have been performed in Asian
populations; the atheroma regression by pioglitazone ob-
served can vary according to races.

4 Discussion

Since their first discovery as antiglycemic drugs in 1990,
glitazones have gained interest as potential pharmaco-
logical targets for other disorders. They have multiple
DNA-mediated effects that make them potential antifi-
brotic agents. Atheroma represents an important bio-
logic model of fibrotic pathology, comprising diseases
such as liver cirrhosis, pulmonary vascular disease, pul-
monary fibrosis, and finally age-related male infertility
and androgen decline due to under-studied vascular and
atherosclerotic changes within the testicular tissue [21].
The potential regenerative therapeutic ability of pioglitaz-
one on atheroma regression will be useful to patients
with coronary or cerebrovascular diseases, as well give
hope to diseased patients suffering from the aforemen-
tioned disorders [22–24].

In our study, we have examined the role of pioglitazone
as an antidiabetic agent for the induction of ather-
oma regression in diabetic patients, which was
demonstrated in six series comprising a total of 1180 pa-
tients who received pioglitazone vs. other antidiabetic
agents. Our study has proved a statistically significant
difference between pioglitazone and other alternative
therapies, namely glimepiride and gliclazide, in decreas-
ing CIMT as shown in Fig. 1. This superior effect could
not be proved on AV by IVUS as shown in Fig. 2.

IMT is the earliest lesion to develop in the context of
atherosclerosis, which could explain why pioglitazone
has an effect on CIMT rather than atheroma volume.
An established atheroma can be more resistant to any
antifibrotic treatment, thus needing more time to
achieve palpable results. Two out of the three studies
that assessed the effect of pioglitazone had a relatively
short duration, namely Ogasawara et al. and Nakayama
et al. [7, 10]. More effect could have been achieved if the
period of the clinical trial would have been extended
[25].

The exact mechanisms by which pioglitazone reverse
atheroma and fibrosis are not completely understood.
In our study, pioglitazone achieved no superior effect
compared to other antidiabetic agents in the control of
hyperglycemia or in reducing LDL lipoproteins. This
suggests that pioglitazone operates through other mech-
anism to allow for the regression of atherosclerosis.

Fig. 3 Effect of pioglitazone vs. other antidiabetic agents on HbA1c. CI, confidence interval; HbA1c, glycated hemoglobin; \( \hat{I} \), heterogeneity; IV, intravitreal; SD, standard deviation; Z, overall effect

Fig. 4 Effect of pioglitazone vs. other antidiabetic agents on LDL. CI, confidence interval; LDL, low-density lipoproteins; SD, standard deviation; Z, overall effect
the release of different injurious agents such as transforming growth factor (TGF), fibroblast growth factor (FGF), and vascular cell adhesion molecule (VCAM). These key players and other molecular targets can be directly downregulated by the epigenetic mechanisms exerted by pioglitazone [26, 27].

Furthermore, the correlation between pioglitazone use and HDL levels suggests that it is through an HDL-mediated mechanism that pioglitazone is able to achieve changes in athereoma volume and carotid intimal media thickness. This finding is supported by other studies which found a strong association between elevated non-HDL levels and other body mass parameters with CIMT in particular [18]. The study suggests that atherosclerotic pathology and its progression is more so factored by CIMT rather than plaque burden, and that this effect is mediated by cholesterol levels [18]. Through its antiatherogenic effects, by means of a reverse cholesterol transport pathway, elevated levels of HDL are an established method to decrease the risk of cardiovascular injury. The search for new and effective drugs for this purpose continues, and of particular interest are drugs that can increase endogenous levels of HDL, such as pioglitazone, rather than the use of exogenous substances that only mimic the effect of HDL [19].

Kardassis and colleagues showed that glitazones can improve the expression of HDL genes which go in agreement with our findings [28].

Decreased HDL levels are an established part of every level of athereoma pathophysiology whereby the mechanisms of (1) inhibiting monocyte adhesion to endothelial cells at sites of plaque formation, (2) promoting NO production which suppresses proliferation of the plaque, (3) promoting fibrinolysis, and (4) preventing intra-plaque hemorrhage and many other pleiotropic effects are lost in the setting of decreased HDL levels [19].

### 5 Conclusion

The role of pioglitazone in the induction of athereoma regression in diabetic patients has been confirmed through our series. This effect seems to be independent of the antglycemic and antidiyslipidemic effects of glitazones. Glitazones might operate through decreasing the yield of vascular pro-inflammatory molecules or through increasing the expression of HDL genes as proven by Kardass et al. Longer duration studies are needed to consolidate the beneficial effects of glitazones on athereoma volume. Also, new clinical trials exploring pioglitazone effects against statins and new antidiabetic agents should be initiated to consolidate the role of pioglitazone. Such proof may help in re-tailoring the therapeutic protocols of diabetic patients with atherosclerosis, making abandoned glitazones as a first option again. Also, athereoma is an important biological model for organ fibrosis that is encountered in many other disorders, such as liver cirrhosis and pulmonary vascular disease. The confirmed effect offers a new hope to many patients on organ transplantation waiting list and officially unleashes the potential of glitazones as members of regenerative pharmacology.
Abbreviations
AV: Atheroma volume; CMT: Carotid intima media thickness; DNA: Deoxynucleobase acid; DM: Diabetes mellitus; HbA1C: Glycated hemoglobin; HDL: High-density lipoprotein; IVUS: Intraventricus ultrasound; LDL: Low-density lipoprotein; NO: Nitric oxide; PPAR: Peroxisome proliferator-activated receptors; RCT: Randomized controlled trials

Acknowledgements
To our families who are bearing the weight of our sacrifice of time to our patients. If our families were not understanding to the depth of our struggle, we would have never been able to keep the same level of dedication to our patients. To our students that we involve in each step of our researches to make them flourish in this field and take the lead the sooner the possible.

Authors’ contributions
AFA and HI contributed to the conception and design of the work. AA, BA, IB, and SG contributed significantly to the acquisition of data. AFA, AA, HI, BA, IB, SG, GA, NA, PA, EM, RM, KB, and MA contributed to the analysis and interpretation of data. RM contributed to the drafting and revision of the manuscript. All authors have approved the submitted version. All authors have agreed both to be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.

Funding
This research received no specific grant from any funding agency or commercial or not-for-profit sectors.

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Pediatric Cardiology Department, Cairo University, Cairo, Egypt. 2Research accessibility Team, Students and Interns Research Program, Cairo University, Cairo, Egypt.

Received: 6 October 2020 Accepted: 8 January 2021
Published online: 03 February 2021

References
1. Gabriels C et al (2014) A different view on predictors of pulmonary hypertension in secundum atrial septal defect. Int J Cardiol 176:833–840
2. Ng-Blichfeldt, J. P., Gosens, R., Dean, C., Griffiths, M. & Hind, M. Regenerative pharmacology for COPD: breathing new life into old lungs. Thorax 1–8 (2019). doi:https://doi.org/10.1136/thoraxjnl-2018-212630
3. Afdal P, AbdelMassih AF (2018) Is pulmonary vascular disease reversible with PPAR γ agonists? Microcirculation 25:1006–1012
4. Afdal, P. et al. Peroxisome proliferator-activated receptor agonists and reversal of vascular degeneration through DNA repair, a step toward drug-induced regenerative medicine. Cardiovasc. Endocrinol. Metab. Publish. Aah, 14–17 (2020), ahead of print.
5. Sheikhpouri M, Abolfathi H, Khatami S, Meshkani R, Barghi TS (2020) The interaction between gene profile and obesity in type 2 diabetes: a review. Obes Med. 181:0197.
6. Kakkar, M. et al. Exploration of combined effect of peroxisome proliferator activated receptor (PPAR) agonist and retinoic acid receptor (RAR) agonist on experimental models of inflammation in rats. Obes Med. 100260 (2020). doi:https://doi.org/10.1016/j.obmed.2020.100260
7. Ogawara D et al (2009) Pioglitazone reduces the necrotic-core component in coronary plaque in association with enhanced plasma adiponecin in patients with type 2 diabetes mellitus. Circ J. 73:343–351
8. Nissen SE et al (2008) Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299:1561–1573
9. Park JS et al (2007) The effects of pioglitazone on cerebrovascular resistance in patients with type 2 diabetes mellitus. Metabolism. 56:1081–1086
10. Nakayama T et al (2010) Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound. Int J Cardiol. 138:157–165
11. Kanazawa I et al (2010) Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus. Osteoporos Int 21:2013–2018
12. Mazzone T et al (2006) Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. J Am Med Assoc. 296:2572–2581
13. WHO. Non-communicable diseases fact sheet. Public Heal An action Guid Improv Heal. (2018). doi:https://doi.org/10.1093/acprof:oso/9780199238934.003.15
14. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. https://doi.org/10.1016/j.jclinepi.2009.09.006
15. Higgins JPT et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. https://doi.org/10.1136/bmj.d9298
16. Koshiyama H, Shimono D, Kuvamura N, Minamikawa J, Nakamura Y (2001) Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 86:3452–3456
17. Nozue T et al (2012) Impact of diabetes mellitus on coronary atherosclerosis and plaque composition under statin therapy - subanalysis of the TRUTH study. Circ J. 76:2188–2196
18. Dormandy JA et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROActive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial. Lancet 366:1279–1289
19. Liu, Xiaole et al (2017)”Comparison of Antidiabetic Medications during the Treatment of Atherosclerosis in T2DM Patients,” Mediators of inflammation 2017: 5032708. https://doi.org/10.1155/2017/5032708
20. Sterne JAC et al (2019) Rob 2: a revised tool for assessing risk of bias in randomised trials. BMJ348:98. https://doi.org/10.1136/bmj34898
21. Akinola OB, Dosumu OC, Sanusi SA, Ajayi TF, Olajide TH (2015) PPAR-γ agonist pioglitazone improves semen quality and testicular histomorphometrics with partial reversal of hyperglycaemia in allaxon-induced diabetic rats. Middle East Fertil Soc J. 20:271–279
22. Libby P (1996) Atheroma: more than mush. Lancet 348:1006–1012
23. Kisseleva T, Brenner DA (2006) Hepatic stellate cells and the reversal of fibrosis. J Gastroenterol Hepatol (Australia). https://doi.org/10.1111/j.1440-1746.2006.04584.x
24. Ebel C et al (2014) A human ex vivo atherosclerotic plaque model to study lesion biology. J Vis Exp. https://doi.org/10.3791/50542
25. Ersoy M, Selcuk Duru HN, Elevli M, Ensoy O, Civilbali M (2015) Aortic intima-media thickness and mean platelet volume in children with type 1 diabetes mellitus. Iran J Pediatr. 25:1006–1012
26. Sabatino L, Fucci A, Pancione M, Colantuoni V (2012) PPARγ epigenetic deregulation and its role in colorectal tumorigenesis. PPAR Res. doi: https://doi.org/10.1155/2012/687492
27. Higashi K et al (2010) Additive antifibrotic effects of pioglitazone and candesartan on experimental renal fibrosis in mice. Nephrology. https://doi.org/10.1111/j.1440-1797.2009.01253.x
28. Kardassis D, Galfencu A, Zannis VI, Daivalos A (2015) Regulation of HDL genes: transcriptional, posttranscriptional, and posttranslational. Handb Exp Pharmacol 224:113–179

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.